Goldman Sachs
IMCR icon

Goldman Sachs’s Immunocore IMCR Stock Holding History

Goldman Sachs’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-46,700
Closed -$3.04M – 5781
2024
Q1 		$3.04M Buy
+46,700
New +$3.2M ﹤0.01% 3532
2023
Q4 		– Sell
-7,200
Closed -$374K – 5722
2023
Q3 		$374K Buy
+7,200
New +$426K ﹤0.01% 4792

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Goldman Sachs's IMCR Position: Q2 2026 in Review

Goldman Sachs increased its Immunocore (IMCR) stake by 15% in Q2 2026, buying an estimated $527K and bringing the position to 137,326 shares worth $4.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3994.

Goldman Sachs first reported a position in IMCR in Q4 2022 and has held it in 15 quarters since. The position peaked at $7.05M in Q3 2024. 135 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Goldman Sachs held 137,326 shares of Immunocore worth $4.36M as of Q2 2026.
  • Goldman Sachs bought 17,829 Immunocore shares in Q2 2026, an estimated $527K.
  • Immunocore made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3994 holding.
  • Goldman Sachs first reported a position in Immunocore in Q4 2022 and has held it in 15 quarters since.
  • Goldman Sachs's Immunocore position peaked at $7.05M in Q3 2024.
  • 135 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.